Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Tottori University Hospital |
---|---|
Information provided by: | Tottori University Hospital |
ClinicalTrials.gov Identifier: | NCT00663377 |
The purpose of this study is to evaluate the effects of losartan, an ARB, on glucose metabolism and inflammatory cytokines in CHF patients treated with ACE inhibitors.
Condition | Intervention | Phase |
---|---|---|
Heart Failure |
Drug: losartan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | Losartan Improved Insulin Resistance and Decreased Inflammatory Cytokines in Patients With Chronic Heart Failure Treated With Angiotensin Converting Enzyme Inhibitors |
Estimated Enrollment: | 16 |
Study Start Date: | April 2006 |
Study Completion Date: | March 2007 |
Chronic heart failure (CHF) is associated with marked insulin resistance, characterized by both fasting and stimulated hyperinsulinemia. Furthermore, insulin resistance is a predictor of CHF and associated with more severe disease and a worse prognosis in patients with CHF. In CHF patients, therefore, insulin resistance is not merely a function of adiposity and may have implications in the pathophysiology of CHF disease progression. Angiotensin II negatively modulates insulin-mediated actions by regulating multiple levels of the insulin signaling cascade such as the insulin receptor, IRS, and PI3-kinase. Furthermore, both ACE inhibitors and angiotensin II receptor blockers (ARB) improve glycemic status not only in patients with type II diabetes but also in patients with hypertension and the metabolic syndrome. On the other hand, it is well known that some cytokines, such as TNF-α, are involved with pathophysiology of insulin resistance and CHF. However, it is still unclear whether the ARB improves insulin resistance in CHF patients already treated with ACE inhibitors and whether there is the relationship between insulin resistance and inflammatory cytokines in CHF patients already treated with ACE inhibitors. Therefore, the purpose of this study is to evaluate the effects of losartan, an ARB, on glucose metabolism and inflammatory cytokines in CHF patients treated with ACE inhibitors.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Center for Clinical Residency Program, Tottori University Hospital ( Kazuhide Ogino ) |
Study ID Numbers: | #656 |
Study First Received: | April 18, 2008 |
Last Updated: | April 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00663377 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Heart Failure Insulin Resistance Losartan ACE inhibitor Inflammatory cytokine |
Heart Failure Losartan Heart Diseases Metabolic Diseases Cardiovascular Agents Angiotensin II Antihypertensive Agents Insulin |
Protease Inhibitors Angiotensin II Type 1 Receptor Blockers Hyperinsulinism Angiotensin-Converting Enzyme Inhibitors Insulin Resistance Anti-Arrhythmia Agents Glucose Metabolism Disorders Metabolic Disorder |
Heart Failure Losartan Heart Diseases Metabolic Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |
Protease Inhibitors Angiotensin II Type 1 Receptor Blockers Hyperinsulinism Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Cardiovascular Diseases Anti-Arrhythmia Agents Insulin Resistance Glucose Metabolism Disorders |